LOGIN OR REGISTER
Course Library

The Breast Cancer Continuum Virtual Study Sessions

Hematology-Oncology
Curriculum:
The Breast Cancer Continuum: Current and Novel Treatment Strategies
Credits:
1 ANCC Contact Hours 1 AMA PRA Category 1 Credit(s) ™
Launch Date:
January 15, 2015
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Medical oncologists; surgeons; radiation oncologists; researchers; oncology nurses; and other healthcare providers involved in the treatment and management of patients with breast cancer.

Relevant Terms:

Breast Cancer

Edith A. Perez, MD

Edith A. Perez, MD
Deputy Director at Large, Mayo Clinic Cancer Center
Group Vice Chair, Alliance for Clinical Trials in Oncology
Serene M. and Frances C. Durling Professor of Medicine
Mayo Clinic - Jacksonville
Jacksonville, Florida

Edith A. Perez, MD, is the Deputy Director at Large for Mayo Clinic Cancer Center in Florida, Group Vice Chair of the Alliance for Clinical Trials in Oncology, Director of the Breast Program, and the Serene M. and Frances C. Durling Professor of Medicine at Mayo Medical School. She is also Chair of the Mayo Clinic Breast Cancer Translational Genomics Program started in 2009 and Chair of the Breast Cancer Specialty Council formed in 2012. She is a cancer specialist and an internationally known translational researcher at Mayo Clinic. Her roles extend nationally, including positions within Mayo Clinic, the American Association for Cancer Research, the American Society of Clinical Oncology, and the National Cancer Institute.
 
Dr. Perez has developed, and is involved in, a wide range of clinical trials exploring the use of new therapeutic agents for the treatment and prevention of breast cancer. She leads and has helped develop basic research studies to evaluate the role of genetic markers in the development and aggressiveness of breast cancer. She has authored more than 690 research articles in journals, books, and abstracts. Dr. Perez is invited frequently to lecture at national and international meetings. She serves on the editorial boards of multiple academic journals.

William J. Gradishar, MD, FACP

William J. Gradishar, MD, FACP
Betsey Bramsen Professor of Breast Oncology
Professor of Medicine
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Dr. William J. Gradishar is Betsy Bramsen Professor of Breast Oncology in the Division of Hematology and Medical Oncology, Department of Medicine, at the Feinberg School Medicine at Northwestern University in Chicago, Illinois, and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. He serves as Director of the Maggie Daley Center for Women's Cancer Care. He has been Chair of the Annual Lynn Sage Breast Cancer Symposium since its inception. His research focuses on the development of novel therapeutics for the treatment of breast cancer. Dr. Gradishar received his medical degree from the University of Illinois Abraham School Of Medicine in Chicago. He completed a residency and chief residency in internal medicine at Michael Reese Hospital and Medical Center in Chicago and a clinical research fellowship in medical oncology at the University of Chicago.
 
A Fellow of the American College of Physicians, Dr. Gradishar is also a member of the American Association for Cancer Research, the American Federation for Clinical Research, and the Association of Subspecialty Professors. He is past chair of the Oncology Training Program Committee and Communications Committee of the American Society of Clinical Oncology (ASCO). He is Chair-elect of the ASCO Professional Development Committee as well as a member of ASCO's Scientific Program Committee. He is a member of the Breast Cancer Core Committee and Co-Chair of the Developmental Therapeutics Working Group of the Eastern Cooperative Oncology Group, the Committee on Cancer of the American College of Surgeons, the National Comprehensive Cancer Network (NCCN) Breast Cancer Guidelines Panel, and the NCCN Breast Cancer Prevention Panel. In addition, he serves as a consultant to the Oncology Drug Advisory Committee of the FDA. He has served on numerous study sections including: NIH, NCI, ACS, Komen, and Alberta Cancer Board. He is a member of the editorial board for numerous journals, including Journal of Clinical Oncology, Oncology, Clinical Breast Cancer, Journal Watch, European Journal of Clinical and Medical Oncology and Clinical Cancer Research. He has published in the area of breast cancer therapeutics, with a focus on new endocrine therapy, chemotherapy and biologic agents. Dr. Gradishar was recently awarded the Betsy Bramsen Endowed Chair of Breast Oncology at Northwestern University.

Joyce A. O'Shaughnessy, MD

Joyce A. O'Shaughnessy, MD
Co-Director, Breast Cancer Research Program
Baylor-Sammons Cancer Center
Texas Oncology
Dallas, Texas

Joyce A. O'Shaughnessy, MD, is Co-Director of the Breast Cancer Research Program at Baylor-Sammons Cancer Center in Dallas, Texas. She is a Diplomate of the American Board of Internal Medicine with subspecialty certification in medical oncology. Dr. O'Shaughnessy focuses on breast cancer biology diagnostics and treatment. She is Co-Chair of the Breast Cancer Research Program at Baylor-Sammons Cancer Center and for The US Oncology Network. She also holds the Celebrating Women Chair in Breast Cancer Research at Baylor-Sammons Cancer Center.
 
Dr. O'Shaughnessy is a member of the American Association for Cancer Research, American Society of Clinical Oncology, American Medical Women's Association, American Medical Association, American College of Physicians, and Women in Cancer Research. She is the Associate Editor for the Clinical Breast Cancer Journal and Founder of The School of Breast Oncology. Dr. O'Shaughnessy received her Doctor of Medicine degree from Yale University Medical School.

Joseph A. Sparano, MD

Joseph A. Sparano, MD
Associate Chairman
Professor of Medicine & Women's Health
Montefiore Medical Center
Bronx, New York

Dr. Joseph Sparano is Professor of Medicine & Women's Health at the Albert Einstein College of Medicine, Associate Chairman for Clinical Research in the Department of Oncology at Montefiore Medical Center, and Associate Director for Clinical Research at the Albert Einstein Cancer Center. He also serves as Vice Chair of the Eastern Cooperative Oncology Group (ECOG) and Vice-Chairman of the AIDS Malignancy Consortium.  His research has focused on developmental therapeutic approaches for breast cancer, lymphoma, and HIV-associated cancers, and therapeutic applications of genomic profiling in cancer.
1. Analyze key pathologic and molecular findings in the identification and diagnosis of early-stage, locally advanced, and metastatic breast cancers
2. Determine optimal sequencing and duration for individualized treatments for HER2+ patients with MBC
3. Evaluate the benefits of mTOR inhibitors, non-taxane microtubules, epothilones, antibody-drug conjugates, and other agents for MBC
4. Assess the optimal use of hormonal therapy in patients with breast cancer
5. Apply current and emerging evidence supporting VEGF and other targeted therapy in breast cancer treatment
6. Utilize prognostic assays in determining treatments for patients with breast cancer
7. Incorporate current treatment guidelines into decision-making for treating patients with breast cancer

Postgraduate Institute for Medicine and AXIS Medical Education, Inc. cordially invite participants of the CME/CE-certified virtual grand rounds activity entitled, "The Breast Cancer Continuum: Intersecting Current and Novel Treatment Strategies In Clinical Practice," to participate in the follow-up Virtual Study Groups. This series of 3 Virtual Study Groups will extend the learnings from the virtual grand rounds, which focused on the pertinent clinicopathologic and therapeutic approaches for managing patients across breast cancer continuum:
 
  • Virtual Study Group 1: Pathological and Molecular Concerns in Breast Cancer
  • Virtual Study Group 2: Early-Stage Breast Cancer Treatment
  • Virtual Study Group 3: Locally Advanced/Metastatic Breast Cancer Treatment
The content of each virtual study group will emphasize a multidisciplinary team-based approach to provide insight on the optimal treatment of patients with breast cancer in order to improve patient outcomes.
 
Estimated Time To Complete Activity:  1 hour
 
Fee Statement 
There is no fee for this educational activity.

Physician Continuing Medical Education 
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and AXIS. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Medical Education
Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Credit Designation
This educational activity for 1.0 contact hours is provided by Postgraduate Institute for Medicine.

Method of Participation
To receive acknowledgement of participation for this CME/CE-certified activity, you must complete the evaluation and pass the posttest online with a score of 65% or better in a maximum of 10 attempts. You may print and/or download your certificate upon completion.

If you have questions regarding the receipt of your certificate or for general inquiries regarding this activity, please contact PIM at 303.799.1930 or via email at inquiries@pimed.com.

Media:  Internet

Disclosure of Conflicts of Interest 
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Edith A. Perez, MD, has no real or apparent conflicts of interest to report.
 
William J. Gradishar, MD, FACP, has no real or apparent conflicts of interest to report.
 
Joyce A. O'Shaughnessy, MD, reported a financial interest/relationship or affiliation in the form of: Consulting Fees (e.g., advisory board), Arno Therapeutics, Celgene Corporation, Corcept Therapeutics, Eisai Inc., Genentech, Inc., GlaxoSmithKline plc., Johnson & Johnson Pharmaceutical Research & Development, LLC, Lilly USA, Med Fusion, LLC, Merrimack Pharmaceuticals, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Pfizer, Inc., sanofi US.
 
Joseph A. Sparano, MD, reported a financial interest/relationship or affiliation in the form of: Consulting Fee, Eisai Inc., Genentech, Inc.; Speakers' Bureau, Celldex, Inc., Genentech, Inc.
  
The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Linda Gracie-King, MS, Deborah Middleton, MS and Diedrea White, BA, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use 
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer 
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Safeguards Against Commercial Bias 
Postgraduate Institute for Medicine and AXIS affirm that the content and format of the CME activities and related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, Postgraduate Institute for Medicine and AXIS employ several strategies to ensure the absence of commercial bias, including, but not limited to, review of all planned content for CME activities jointly sponsored by Postgraduate Institute for Medicine and AXIS to ensure adherence to the Accreditation Council for Continuing Medical Education's content validation statements, and resolution of any actual or perceived conflicts of interest that exist. We employ three metrics as we review materials:

1. Fair balance
  1. Recommendations or emphasis must fairly represent and be based on a reasonable and valid interpretation of the information available on the subject matter
  2. No single product or service is overrepresented when other equal competing products or services are available for inclusion
2. Scientific objectivity of studies mentioned in the materials or used as the basis for content
3. Appropriateness of patient care recommendations made to learners
 
Jointly provided by
 
                       

This activity is supported by an independent educational grant from Genentech, Inc. For further information concerning Genentech grant funding, visit www.gene.com/good/grants-giving/imed.
 
COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8   
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 5.0+ for Mac OSX 10.5 and above

For video playback, install the latest version of Flash or Quicktime.

Schedule an event with a Standardized Patient
×